DSM Biomedical develops polymer platform for artificial hips and
knees
9 October 2009
DSM Biomedical has developed a new polyethylene polymer platform
intended to improve the mechanical properties and long-term stability of
hip and knee implants.
In 2007, DSM Biomedical commenced an R&D program focused on improving
ultra high molecular weight polyethylene (UHMWPE) use in artificial
joints. Although UHMWPE has been used for more than 45 years in
artificial joints, improvements in the material’s wear resistance are
still necessary to help avoid revision surgeries.
Cross-linking, a technique using high radiation doses, significantly
improved wear resistance, but with adverse effects on the polymer’s
mechanical properties.
Since the initiation of its UHMWPE R&D program two years ago, DSM
Biomedical has now developed an easily cross-linkable UHMWPE. The newly
developed polymer platform creates a family of UHMWPE-polymers that
incorporate small, highly reactive molecules that can produce the
required cross-linking network at significantly lower radiation doses,
thereby lessening the adverse effects on the polymer’s mechanical
properties and allowing for stronger implants with better long-term
stability. DSM Biomedical says it is the first company to apply this
technique to UHMWPE.
“Nearly two million people receive artificial hips or knees each
year, and the artificial joint market continues to grow in conjunction
with trends associated with an aging population and increases in
obesity, among others,” said Leo Smit, Business Director for Implants,
DSM Biomedical. “We believe that this platform will lead to more stable
implants and help reduce the number of revision surgeries needed.”
“The conception and realization of this platform are the result of a
significant investment in R&D,” said Steve Hartig, President of DSM
Biomedical. “This development underscores our commitment to building a
portfolio of biomedical products to help meet both current and future
clinical needs in the orthopaedic market.”
DSM Biomedical says it has filed a patent on this polymer platform
and its application in total joint arthroplasty. Now that the DSM
research team has been able to demonstrate the easily cross-linkable
behaviour, the research is currently focusing on the optimization of the
mechanical properties of the polymer. DSM Biomedical expects to be
working closely with a number of the major orthopaedic companies on the
final development of the material.
Bookmark this page